| 13:00-14:00, Auditorium 8 |
| BIOTRONIK |
SY 401 | Modern day explorers:
how technology influences outcomes |
| |
| Moderator: M. Brodmann
(Graz/AT) |
| |
401.1
401.2
401.3
401.4
| DCB: discover the science behind coating technology
M. Gratz (Buelach/CH)
BIOFLEX PEACE Registry interim analysis: navigating complex disease
through evidence
C. Nolte-Ernsting (Mühlheim/DE)
Stent design: a pioneering scientific viewpoint on radial force
K. Deloose (Dendermonde/BE)
BIOFLEX-COF: venturing beyond the concept of high radial force
M.A. Funovics (Vienna/AT) |
| |
| |
| 13:00-14:00, Auditorium 6 |
| Philips |
SY 402
| Making the difference
with Philips Live Image Guidance: update on live image guidance in
interventional oncology |
| |
| Moderator: J.-F.H.
Geschwind (New Haven, CT/US) |
| |
402.1
402.2
402.3
| Improved intraprocedural depiction of primary and secondary
liver tumours:
3D HQ imaging with Dual-Phase XperCT Open
R.E. Schernthaner (Vienna/AT)
Seeing where you embolise – visibility of a novel radiopaque bead during
image-guided interventions – an animal model
K. Sharma (Washington, DC/US)
Novel approaches for ablation and embolisation with ultrasound, Dual-Phase
CBCT and OncoSuite
G. Carrafiello (Varese/IT) |
| |
| |
| 13:00-14:00, Auditorium 2 |
| Surefire Medical, Inc. |
SY 403
| Precision delivery in
cancers of the liver: improved targeting with the Surefire System |
| |
| Moderator: M. van den
Bosch (Utrecht/NL) |
| |
403.1
403.2
403.3
403.4
| Overview of the Surefire technology and SIM study update
M. van den Bosch (Utrecht/NL)
Utilisation of Surefire for primary liver cancer
P.P. Goffette (Brussels/BE)
Utilisation of Surefire for secondary liver cancer
G.A. Maleux (Leuven/BE)
Surefire in action: unique case examples
F. Wolf (Vienna/AT) |
| |
| |
| |
Sunday, September 27,
2015TOP |
| |
| 08:00-08:20, Room 3.A |
| PharmaCept |
SY 801
| DSM-TACE (EmboCept® S)
in comparison with cTACE and
DEB-TACE: first results
of VEGF levels under the treatment |
| |
| Moderator: P.L. Pereira
(Heilbronn/DE) |
| |
801.1
801.2
| Impact of DSM-TACE on VEGF levels in HCC patients
P. Wiggermann (Regensburg/DE)
Evaluation of VEGF levels under cTACE in HCC patients
P.L. Pereira (Heilbronn/DE) |
| |
| |
| 08:00-08:20, Auditorium 2 |
| Bolton Medical |
SY 802 | Aortic by design |
| |
| Moderators: P. Cao
(Rome/IT), V. Riambau (Barcelona/ES) |
| |
802.1
802.2
| TREO: from evidence to clinical practice
J.P. Henretta (Asheville, NC/US)
Why a custom made programme for abdominal repair?
C. Engelke (Goettingen/DE) |
| |
| |
| 11:30-12:30, Auditorium 6 |
| BTG |
SY 1101
| Evolving patient
centric strategies (in HCC): the role of interventional
oncology |
| |
| Moderators: R. Sharma
(Oxford/UK), J. Urbano (Madrid/ES) |
| |
1101.1
1101.2
| DC BeadM1™ in
HCC – initial results of extensive patient study
C. Aliberti (Padova/IT), R. Carandina
(Padova/IT)
Integrating radioembolisation into the longitudinal management of HCC
A. Dechene (Essen/DE) |
| |
| |
| 11:30-12:30, Auditorium 1 |
| Cordis |
SY 1102 | The femoral popliteal
segment: can we make the final balance? |
| |
| Moderator: J.A. Reekers
(Amsterdam/NL) |
| |
1102.1
1102.2
1102.3
1102.4
| From PTA to drug-eluting technology: have we reached the final
goal?
F. Fanelli (Rome/IT)
Obstructive disease in the popliteal treatment: when and how should stenting
be performed?
S. Müller-Hülsbeck (Flensburg/DE)
Indications for SFA treatment and the SMART® Flex Vascular Stent clinical
programme
W.A. Gray (New York, NY/US)
Femoral-popliteal interventions and outcome: the missing link
J.A. Reekers (Amsterdam/NL) |
| |
| For healthcare professionals only. This symposium has been
made possible through an educational support from Cordis. |
| |
| |
| 11:30-12:30, Auditorium 8 |
| Penumbra |
SY 1103
| Changing the paradigm
of peripheral treatment in embolisation and
thrombectomy |
| |
| Moderator: P. Quaretti
(Pavia/IT) |
| |
1103.1
1103.2
1103.3
| Indigo System with venous indication: do we finally have the
solution for arterial and venous clot management?
J.F. Benenati (Miami, FL/US)
The importance of packing density in peripheral embolisation through
utilisation of Ruby Large Volume Coil and POD Occlusion System
L.P. Moramarco (Pavia/IT)
CGuard – MicroNet covered embolic prevention carotid stent system: a
game-changer in CAS
P. Musialek (Krakow/PL) |
| |
| |
| 13:00-14:00, Auditorium 6 |
| Merit Medical |
SY 1201 | Transradial approach in
interventional radiology |
| |
| Moderator: C.A. Binkert
(Winterthur/CH) |
| |
1201.1
1201.2
1201.3
| IR suite configuration, setup and nuances for the transradial
procedure
C.A. Binkert (Winterthur/CH)
Transcatheter directed liver therapy via transradial approach
D. Klass (Vancouver, BC/CA)
Uterine fibroid embolisation (UFE) via transradial approach
A.M. Fischman (New York, NY/US) |
| |
| |
| 13:00-14:00, Auditorium 2 |
| Straub Medical AG |
SY 1202
| Mechanical debulking in
arteries and its importance in optimisation of endovascular therapy |
| |
| Moderator: M.G. Manzi
(Abano Terme/IT) |
| |
1202.1
1202.2
1202.3
1202.4
| The inflammatory response inside the vessel wall and its
influence on treatment
outcomes
P. Minko (Homburg/DE)
Mechanical debulking with Rotarex®S – unmask the underlying
stenosis and treat the real problem
M. Katoh (Krefeld/DE)
Acute and subacute ischaemia of the lower limb – can mechanical debulking
replace surgery and thrombolysis?
M. Bulvas (Prague/CZ)
Chronic occlusions and stenoses – can mechanical debulking with Rotarex®S
reduce the stent length as well as the number of implanted stents?
M. Bulvas (Prague/CZ) |
| |
| |
| 13:00-14:00, Auditorium 8 |
| Terumo Europe |
SY 1203 | How I pushed my
boundaries in the treatment of… |
| |
| Moderator: C. Setacci
(Siena/IT) |
| |
1203.1
1203.2
1203.3
1203.4
| Complex and difficult to access carotid lesions
A. Cappelli (Siena/IT)
Multi vessel lesions in lower limbs
T. Fuss (Bern/CH)
Complex atherosclerotic popliteal artery disease
I. Kralj (Rastatt/DE)
Critical limb ischaemia
L.M. Palena (Abano Terme/IT) |
| |
| |
| 14:30-15:30, Auditorium 6 |
| Medtronic |
SY 1303 | Ablation with
ThermosphereTM technology: 1 year follow-up |
| |
| Moderator: T. de Baère
(Villejuif/FR) |
| |
1303.1
1303.2
1303.3
| Predictability of ablation shape with ThermosphereTM technology
G. Carrafiello (Varese/IT)
Lung thermal ablations with ThermosphereTM technology
T.J. Vogl (Frankfurt/DE)
Renal tumour treatments with ThermosphereTM technology
W. Prevoo (Amsterdam/NL) |
| |
| |
| 15:40-16:00, Auditorium 8 |
| TVA Medical |
SY 1304 | Endovascular AVF
creation with the everlinQ AVF System |
| |
| Moderator: D.K. Rajan
(Toronto, ON/CA) |
| |
1304.1
1304.2
| everlinQ endoAVF overview and clinical update
D.K. Rajan (Toronto, ON/CA)
everlinQ endoAVF in action: case studies
J. Clement (Vancouver, BC/CA) |
| |
| |
| 17:30-17:50, Room 3.B |
| Toshiba Medical Systems |
SY 1508 | Changing IR pathways in
Angio-CT using Infinix 4DCT |
| |
| Moderator: A. Gangi
(Strasbourg/FR) |
| |
1508.1 | F.G. Irani
(Singapore/SG) |
| |
| |
| |
Monday, September 28,
2015TOP |
| |
| 07:40-08:20, Room 3.A |
| W.L. Gore &
Associates GmbH |
SY 1601
| TIPS for the treatment
of portal hypertension complications: refractory ascites, variceal bleeding.
A case-based discussion |
| |
| Moderator: G.M. Richter
(Stuttgart/DE) |
| |
1601.1
1601.2
1601.3
| Introduction
G.M. Richter (Stuttgart/DE)
Case presentations
D. Patch (London/UK), D. Yu (London/UK)
Learnings and conclusion
G.M. Richter (Stuttgart/DE) |
| |
| |
| 11:30-12:30, Auditorium 6 |
| Boston Scientific |
SY 1901
| Peripheral arterial
intervention – data, direction and decisions shaping the drug-eluting era |
| |
| Moderators: M.J. Lee
(Dublin/IE), M.G. Manzi (Abano Terme/IT) |
| |
1901.1
1901.2
1901.3
1901.4
1901.5
| Opening and introduction
M.J. Lee (Dublin/IE)
Paclitaxel balloons – current status and Ranger DCB programme
T. Albrecht (Berlin/DE)
Paclitaxel stents – current status and Eluvia DES programme
S. Müller-Hülsbeck (Flensburg/DE)
Implications for our practice
W.A. Gray (New York, NY/US)
Close and take home message
M.G. Manzi (Abano Terme/IT) |
| |
| |
| 11:30-12:30, Auditorium 1 |
| Cook Medical |
SY 1902 | The guide to drug
elution and how to keep SFA treatment simple |
| |
| Moderator: M.D. Dake
(Stanford, CA/US) |
| |
1902.1
1902.2
1902.3
1902.4
1902.5
| Navigating clinical studies
M.A. Funovics (Vienna/AT)
Zilver PTX – global data overview
M.D. Dake (Stanford, CA/US)
The technical evolution of the DES
F. Fanelli (Rome/IT)
TASC C&D lesions – the French experience
J.-P. Becquemin (Créteil/FR)
Why bare balloon angioplasty and bare metal stents are obsolete?
K.N. Katsanos (London/UK) |
| |
| |
| 11:30-12:30, Auditorium 8 |
| Sirtex Medical Europe
GmbH |
SY 1903 | SIRFLOX – a new option
for colorectal liver metastases |
| |
| Moderators: T. de Baère
(Villejuif/FR), J. Ricke (Magdeburg/DE) |
| |
1903.1
1903.2
1903.3
1903.4
| SIRFLOX study and results
N. Schäfer (Lausanne/CH)
SIRFLOX discussion
R. Sharma (Oxford/UK)
Implications for interventional oncology
T.K. Helmberger (Munich/DE)
Implications for the multidisciplinary team (MDT)
J.I. Bilbao (Pamplona/ES) |
| |
| |
| 13:00-14:00, Auditorium 2 |
| Cordis |
SY 2001
| Early experiences in
European radiological and vascular surgical
departments with
INCRAFT® AAA Stent Graft System: a new
development in EVAR
treatment |
| |
| Moderator: F. Fanelli
(Rome/IT) |
| |
2001.1
2001.2
2001.3
2001.4
| Introduction
F. Fanelli (Rome/IT)
Experiences with INCRAFT® System
in a Dutch collaborative vascular surgery and radiology practice
B. Knippenberg (The Hague/NL)
INCRAFT® System:
a cost effective experience in a busy German EVAR centre
A.G. Schwindt (Münster/DE)
INCRAFT® System:
early percutaneous EVAR experience with the Cordis INCRAFT®System
in a large teaching hospital in the United Kingdom
S.D. Goode (Sheffield/UK) |
| |
| For healthcare professionals only. The use of the INCRAFT® AAA Stent-Graft System requires that physicians be specially
trained in endovascular abdominal aortic aneurysm repair techniques,
including experience with high resolution fluoroscopy and radiation safety.
Cordis Corporation will provide training specific to the INCRAFT® AAA Stent-Graft System. |
| |
| |
| 13:00-14:00, Auditorium 8 |
| Guerbet |
SY 2002
| Casting a new light on
evidence-based medicine therapy in interventional
oncology |
| |
| Moderator: R. Lencioni
(Pisa/IT) |
| |
2002.1
2002.2
2002.3
| cTACE fundamentals & insight on the future
J.-F.H. Geschwind (New Haven, CT/US)
cTACE landmark clinical studies, unrivalled overall survival data &
international HCC guidelines
R. Lencioni (Pisa/IT)
The Japanese mastery of superselective cTACE, the Asian perspective
K. Osuga (Osaka/JP) |
| |
| |
| 13:00-14:00, Auditorium 6 |
| Medtronic |
SY 2003
| From straightforward to
complex: review of IN.PACT Admiral DEB evidence in challenging clinical
scenarios |
| |
| Moderators: D.
Karnabatidis (Patras/GR), P. Krishnan (New York, NY/US) |
| |
2003.1
2003.2
2003.3
2003.4
| DCB effectiveness in long SFA lesions: results from IN.PACT
Global Study and
Imaging Cohort
G. Tepe (Rosenheim/DE)
DCB effectiveness in long SFA lesions: experience and clinical evidence from
an
independent study
A. Micari (Cotignola/Palermo/IT)
Beyond long SFA lesions: do current results encourage further expansion of
indications?
K.N. Katsanos (London/UK)
Success with DCB: important technical considerations
P. Krishnan (New York, NY/US) |
| |
| |
| 14:30-15:30, Auditorium 8 |
| Terumo Europe |
SY 2104 | HCC treatment
algorithm: selected topics |
| |
| Moderator: J. Bruix
(Barcelona/ES) |
| |
2104.1
2104.2
2104.3
2104.4
| HCC-BCLC paradigm
J. Bruix (Barcelona/ES)
LifePearl Doxorubicin – first experiences and PK study
K. Malagari (Athens/GR)
Occlusafe potential applications in HCC treatment
T. de Baère (Villejuif/FR)
HCC ablation: RFA vs. MWA
J. Ricke (Magdeburg/DE) |
| |
| |
| 15:30-16:00, Room 5.A |
| Bard |
SY 2105 | When great filter
design meets best practice |
| |
| Moderator: C.A. Binkert
(Winterthur/CH) |
| |
2105.1
2105.2
| Two-year results of the prospective, multicentre Denali retrievable
IVC filter trial
S.W. Stavropoulos (Philadelphia, PA/US)
Patient follow-up and retrievals programmes
S.D. Qanadli (Lausanne/CH) |
| |
| |
| 17:30-18:10, Room 3.B |
| Aachen Resonance
Holding |
SY 2307 | ELUTAX SV |
| |
| Moderator: C. Massa
Saluzzo (Pavia/IT) |
| |
2307.1
2307.2
2307.3
| My experience of treating peripheral lesions with ELUTAX SV
C. Massa Saluzzo (Pavia/IT)
The mid-term clinical follow-up using drug-eluting balloons on tibial artery
“de novo” lesions in patients with critical limb ischaemia. A cohort study
V. Tolva (Milan/IT)
ELUTAX SV – why and how
A. Ruebben (Luxembourg/LU) |
| |
| |
| 17:30-18:30, Auditorium 6 |
| Bard |
SY 2308
| Real world outcomes on
the efficacy and safety of LUTONIX® DCB in
vascular disease |
| |
| Moderator: F. Fanelli
(Rome/IT) |
| |
2308.1
2308.2
2308.3
2308.4
| A study of downstream events of the two leading DCBs on the
market
R. Virmani (Gaithersburg, MD/US)
Lutonix DCB outcomes in LEVANT 2 and real world experience
F. Fanelli (Rome/IT)
BTK advanced techniques and Lutonix DCB experience in BTK
A. Micari (Palermo/IT)
DCB in AV access: how I use Lutonix in my practice
K. Steiner (Stevenage/UK) |
| |
| |
| |
Tuesday, September 29,
2015TOP |
| |
| 13:00-14:00, Auditorium 1 |
| Medtronic |
SY 2801 | Endovascular trauma
management and endoleak management |
| |
| Moderator: J. Urbano
(Madrid/ES) |
| |
2801.1
2801.2
2801.3
| Endovascular trauma management
T. Horer (Örebro/SE)
Embolisation in emergency setting, how to treat?
G. Carrafiello (Varese/IT)
Endoleak type I and II management
R.A. Morgan (London/UK) |
| |
| |
| 13:00-14:00, Auditorium 8 |
| Siemens Healthcare GmbH |
SY 2802 | Impact of
intra-operative cross-modality imaging on patient outcome |
| |
2802.1
2802.2
2802.3
2802.4 | C.T. Sofocleous (New
York, NY/US)
U.K.M. Teichgräber
(Jena/DE)
A. Gangi
(Strasbourg/FR)
J. Golzarian
(Minneapolis, MN/US) |
| |
| |
| 13:00-14:00, Auditorium 6 |
| Terumo Europe |
SY 2803 | From loco-regional
therapies in mCRC to recanalisation |
| |
| Moderator: T.K.
Helmberger (Munich/DE) |
| |
2803.1
2803.2
2803.3
2803.4
| Loco-regional therapies in mCRC: ESMO Guidelines update
D. Arnold (Freiburg/DE)
LifePearl Irinotecan – initial experience and CIRSE Registry
T.K. Helmberger (Munich/DE)
Ablation in mCRC
A. Kovacs (Bonn/DE)
Recanalisation matters!
J.-P. Pelage (Caen/FR) |
| |
